-+ 0.00%
-+ 0.00%
-+ 0.00%

Cartesian Therapeutics signs licensing deal with WestGene Biopharma for in vivo CAR-T platform in autoimmune diseases

PUBT·06/09/2026 11:01:08
Listen to the news
Cartesian Therapeutics signs licensing deal with WestGene Biopharma for in vivo CAR-T platform in autoimmune diseases
  • Cartesian Therapeutics signed a strategic licensing deal with WestGene Biopharma to develop in vivo mRNA CAR-T therapies for autoimmune diseases.
  • Lead program targets generalized myasthenia gravis, pairing Descartes-08 mRNA with WestGene’s targeted lipid nanoparticle delivery to avoid ex vivo manufacturing.
  • Phase 1 dose-escalation trial slated for 2H 2026; initial human data expected in 1H 2027.
  • WestGene to receive an upfront payment, with additional development and commercial milestone payments.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cartesian Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606090700PRIMZONEFULLFEED9733762) on June 09, 2026, and is solely responsible for the information contained therein.